Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis, and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis.
Casale
Roberto
R
Rehabilitation Institute of Montescano, Foundation S. Maugeri-Pavia, IRCCS, Italy.
Generini
Sergio
S
Luppi
Fabrizio
F
Pignone
Alberto
A
Matucci-Cerinic
Marco
M
D018501:Antirheumatic Agents / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000209:etiology; D020551:Pulse Therapy, Drug; D011928:Raynaud Disease / Q000188:drug therapy* / Q000209:etiology; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy*; D013564:Sympathetic Nervous System / Q000187:drug effects
D018501:Antirheumatic Agents; D003520:Cyclophosphamide